» Articles » PMID: 22569881

Rates of Hospitalized Bacterial Infection Associated with Juvenile Idiopathic Arthritis and Its Treatment

Overview
Journal Arthritis Rheum
Specialty Rheumatology
Date 2012 May 10
PMID 22569881
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare the incidence of hospitalized bacterial infections among children with and children without juvenile idiopathic arthritis (JIA) and to examine the effects of selected medications.

Methods: Using national Medicaid data from 2000 through 2005, we identified a cohort of children with JIA and a comparator cohort of children with attention deficit hyperactivity disorder (ADHD). Exposures to methotrexate (MTX), TNF inhibitors, and oral glucocorticoids (GCs) were determined using pharmacy claims. Patients hospitalized with bacterial infections were identified using coded discharge diagnoses. We calculated adjusted hazard ratios (HR(adj) ) to compare infection incidence rates while adjusting for relevant covariates.

Results: We identified 8,479 JIA patients with 13,003 person-years of followup; 36% took MTX and 16% took TNF inhibitors. Compared with ADHD patients, JIA patients who were not currently taking MTX or TNF inhibitors had an increased rate of infection (HR(adj) 2.0 [95% confidence interval (95% CI) 1.5, 2.5]). Among JIA patients not receiving TNF inhibitor therapy, MTX users had a similar rate of infection as those not currently taking MTX (HR(adj) 1.2 [95% CI 0.9, 1.7]). TNF inhibitor use (irrespective of MTX) resulted in a similar rate of infection as use of MTX without a TNF inhibitor (HR(adj) 1.2 [95% CI 0.8, 1.8]). Use of high-dose GCs (≥10 mg/day of prednisone or equivalent) increased the rate of infection as compared with no GC use, after adjustment for MTX and TNF inhibitor use (HR(adj) 3.1 [95% CI 2.0, 4.7]).

Conclusion: Children with JIA had an increased rate of infection compared to children with ADHD. Among children with JIA, the rate of infection was not increased with MTX or TNF inhibitor use, but was significantly increased with high-dose GC use.

Citing Articles

Impact of chronic opioid use on acute health care utilization in children with IBD and arthritis: a retrospective cohort study.

Dagci A, Jiang S, Chang J, Grossman A, Xiao R, Weiss P BMC Pediatr. 2024; 24(1):711.

PMID: 39511521 PMC: 11542491. DOI: 10.1186/s12887-024-05206-y.


Integrative analysis reveals novel insights into juvenile idiopathic arthritis pathogenesis and shared molecular pathways with associated traits.

Pudjihartono N, Ho D, OSullivan J Front Genet. 2024; 15:1448363.

PMID: 39175752 PMC: 11338781. DOI: 10.3389/fgene.2024.1448363.


Patients with juvenile idiopathic arthritis have decreased clonal diversity in the CD8 T cell repertoire response to influenza vaccination.

Sabbagh S, Haribhai D, Gershan J, Verbsky J, Nocton J, Yassai M Front Immunol. 2024; 15:1306490.

PMID: 38873594 PMC: 11169902. DOI: 10.3389/fimmu.2024.1306490.


Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study.

Brunner H, Akikusa J, Al-Abadi E, Bohnsack J, Boteanu A, Chedeville G Ann Rheum Dis. 2024; 83(11):1561-1571.

PMID: 38849152 PMC: 11503147. DOI: 10.1136/ard-2023-225094.


Validation of new medication use algorithms as proxies for worsening disease activity in patients with juvenile idiopathic arthritis.

Saito K, Gabbeta A, Mulvihill E, Al-Jaberi L, Beukelman T, Lewis J Pharmacoepidemiol Drug Saf. 2024; 33(5):e5803.

PMID: 38685851 PMC: 11541400. DOI: 10.1002/pds.5803.


References
1.
Petty R, Southwood T, Manners P, Baum J, Glass D, Goldenberg J . International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004; 31(2):390-2. View

2.
Patkar N, Teng G, Curtis J, Saag K . Association of infections and tuberculosis with antitumor necrosis factor alpha therapy. Curr Opin Rheumatol. 2008; 20(3):320-6. DOI: 10.1097/BOR.0b013e3282fa74f7. View

3.
Lovell D, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K . Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008; 359(8):810-20. DOI: 10.1056/NEJMoa0706290. View

4.
Beukelman T, Patkar N, Saag K, Tolleson-Rinehart S, Cron R, Morgan DeWitt E . 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011; 63(4):465-82. PMC: 3222233. DOI: 10.1002/acr.20460. View

5.
Patkar N, Curtis J, Teng G, Allison J, Saag M, Martin C . Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patients. J Clin Epidemiol. 2008; 62(3):321-7, 327.e1-7. PMC: 2736855. DOI: 10.1016/j.jclinepi.2008.06.006. View